
Elotuzumab is an immunotherapy called a monoclonal antibody. It was approved for use in November of 2015 to be used with lenalidomide and dexamethasone. Researchers are now testing elotuzumab with another drug in the same class of immunomodulator drugs called pomalidomide to see if it has similar impact in the treatment on myeloma. In this study, researchers are comparing pomalidomide and low-dose dexamethasone vs. pomalidomide, low-dose dex and elotuzumab. The trial aims to include over 120 patients and is open in 11 locations in the US. To learn more about this clinical trial, click here: Elotuzumab, Pom, Dex for Relapsed/Refractory Myeloma

about the author
Jennifer Ahlstrom
Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of HealthTree Foundation (formerly Myeloma Crowd).
More on Life With Myeloma
Get the latest thought leadership on Multiple Myeloma delivered straight to your inbox.
Subscribe to the weekly "HealthTree Community for Multiple Myeloma Newsletter" for Multiple Myeloma news, life with Multiple Myeloma stories, Multiple Myeloma clinical trials, Multiple Myeloma 101 articles and events with Multiple Myeloma experts.
Thanks to our HealthTree Community for Multiple Myeloma Sponsors:






.svg_7bb6fd32-1b73-4ca9-9a2f-8fd6fc59d528.png?alt=media)